인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
Most common adverse effect causing cessation of anti-tubercular treatment (ATT) is drug-induced liver injury (DILI) which is unpredictable due to its idiosyncratic nature. ATT is the most common cause of DILI and drug-induced acute liver failure (ALF) in South East Asia. Spectrum of ATT-DILI ranges from asymptomatic raised transaminases to acute hepatitis to acute liver failure (ALF). ALF due to ATT has a more aggressive course with up to 70% mortality. Both modifiable and non-modifiable risk factors are involved. Increasing age, female gender, genetic predisposition, poor nutrition, underlying liver disease, and concomitant viral infections make one prone to ATT-DILI. Thus, pretreatment evaluation is very important. Diagnosis of ATT-DILI is challenging due to lack of specific diagnostic tests; rather, it is a diagnosis of exclusion. Mild transient asymptomatic raised transaminases is due to hepatic adaptation and does not require any modification or cessation of ATT. Early detection of clinically significant DILI by frequent monitoring is associated with better prognosis and low mortality. Prompt withdrawal of all the potential hepatotoxic drugs is the key step in the management. Since the benefit of first-line ATT outweighs the monitored risk, reintroduction is always considered after normalization of raised transaminases. Ideal regimen is sequential reintroduction with incremental dosage of least hepatotoxic drug first, but evidence for this is lacking. Since hepatotoxicity rate is similar across different regimens, reintroduction is individualized based on perceived clinical risk. Future research is needed to identify specific biomarker panel for diagnosing ATT-DILI.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
